https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673
Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
zc:702857855314100125
0
https://www.zacks.com/stock/news/2257263/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2257263
Apr 17, 2024 - Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
zc:-3853056681045333142
0
https://www.zacks.com/stock/news/2248594/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2248594
Apr 01, 2024 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:1599498501236944523
0
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
zc:-7151330197196557010
0
https://www.zacks.com/stock/news/2244204/acelyrin-slrn-up-on-data-from-thyroid-eye-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244204
Mar 21, 2024 - ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
zc:5370351507745646220
0
https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
fool:-6439001316408559179
0
https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077
Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
zc:-6632016347588930676
0
https://www.zacks.com/commentary/2232860/top-research-reports-for-nvidia-visa-amgen?cid=CS-ZC-FT-research_daily-2232860
Feb 28, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).
zc:3063361431494597975
0
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
zc:6928781431631922699
0
https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255
Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
zc:5565331163587547925
0